No Result

View All Result

No products in the cart.

2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑

Home StudyGraphics

#VisualAbstract: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

byWinnie Liu

September 13, 2023

in StudyGraphics

Reading Time: 1 min read

#VisualAbstract: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

Click here to read this study in NEJM.

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Foundayo (Orforglipron) Approval Marks the Beginning of the Oral GLP-1 Era for Obesity Treatment

Orforglipron (Foundayo) expands oral treatment options for weight management

2 Minute Medicine: Pharma Roundup – Geopolitical instability in the Strait of Hormuz threatens global generic drug supply, daraxonrasib improves pancreatic cancer survival, sparsentan (Filspari) approved for focal segmental glomerulosclerosis, glucagon-like peptide-1 receptor agonists linked to reduced substance use disorders, and orforglipron (Foundayo) expands oral weight loss therapy options

Tags: obesity Orforglipron

#VisualAbstract: Pitavastatin reduces cardiovascular event risk among patients with HIV

RelatedReports

Cost-related medication nonadherence associated with increased ED utilization

Pharma

Foundayo (Orforglipron) Approval Marks the Beginning of the Oral GLP-1 Era for Obesity Treatment

September 4, 2026

Combined immunotherapy may improve survival in metastatic pancreatic cancer

Chronic Disease

Orforglipron (Foundayo) expands oral treatment options for weight management

May 8, 2026

Pharma

2 Minute Medicine: Pharma Roundup – Geopolitical instability in the Strait of Hormuz threatens global generic drug supply, daraxonrasib improves pancreatic cancer survival, sparsentan (Filspari) approved for focal segmental glomerulosclerosis, glucagon-like peptide-1 receptor agonists linked to reduced substance use disorders, and orforglipron (Foundayo) expands oral weight loss therapy options

May 4, 2026

Many new pediatric asthma cases attributable to obesity

Cardiology

150 minutes of moderate-to-vigorous physical activity per week may reduce cardiovascular risk in overweight or obese adults

February 26, 2026

CRISPR-mediated gene activation rescues obesity caused by haploinsufficiency [PreClinical]

CRISPR-Cas9 promoting fetal hemoglobin production improves severe sickle cell disease

Postextubation administration of high-flow oxygen leads to reduced reintubation and respiratory failure

Video laryngoscopy leads to higher success on first intubation attempt than direct laryngoscopy

#VisualAbstract: Low-dose glucocorticoids for rheumatoid arthritis do not increase blood pressure

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

#VisualAbstract: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

Foundayo (Orforglipron) Approval Marks the Beginning of the Oral GLP-1 Era for Obesity Treatment

Orforglipron (Foundayo) expands oral treatment options for weight management

#VisualAbstract: Pitavastatin reduces cardiovascular event risk among patients with HIV

CRISPR-Cas9 promoting fetal hemoglobin production improves severe sickle cell disease

RelatedReports

Foundayo (Orforglipron) Approval Marks the Beginning of the Oral GLP-1 Era for Obesity Treatment

Orforglipron (Foundayo) expands oral treatment options for weight management

150 minutes of moderate-to-vigorous physical activity per week may reduce cardiovascular risk in overweight or obese adults

CRISPR-Cas9 promoting fetal hemoglobin production improves severe sickle cell disease

Video laryngoscopy leads to higher success on first intubation attempt than direct laryngoscopy

#VisualAbstract: Low-dose glucocorticoids for rheumatoid arthritis do not increase blood pressure

2MM+ All Access

Recent Reports

The medical literature, distilled daily.

Membership benefits